Coronary and mortality risk of novel oral antithrombotic agents: A meta-analysis of large randomised trials

BMJ Open

Volumn 2, Issue 5, 2012, Pages

  Mak, Koon Hou ^a  

^a Mak Heart Clinic   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; BLEEDING; CORONARY RISK; DRUG EFFECT; DRUG EFFICACY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS THROMBOEMBOLISM;

EID: 84869795745     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001592     Document Type: Article

References (44)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
2. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaulation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012;125:669-76.
3. Uchino K, Hernandez AV . Dabigatran association with higher risk of acute coronary events. Meta-analysis of nononferiority randomized controlled trials. Arch Intern Med 2012;172:372-402.
4. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1-12.
5. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
6. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:1559-73.
7. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
8. Colwell CW Jr, Berkowitz SC, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005;87:2169-77.
9. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56.
10. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85.
11. The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9.
12. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb Haemost 2011;105:721-9.
13. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75.
14. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-19.
15. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
16. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECRORD4): a randomised trial. Lancet 2009;373:1673-80.
17. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
18. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15.
19. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98.
20. Fiessinger J-N, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-9.
21. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
22. Schulman S, Baanstra D, Eriksson H, et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism (abstract). J Thromb Haemost 2011;9:22.
23. Schulman S, Eriksson H, Goldhaber SZ, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism (abstract). J Thromb Haemost 2011;9:731.
24. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
25. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomised trial. Lancet 2003;362:1691-8.
26. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8.
27. Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
28. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
29. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
30. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
31. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9.
32. Mega JL, Braunwald E,Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
33. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 2009;119:2877-85.
34. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
35. Sarich TC, Wolzt M, Eriksson UG, et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 2003;41:557-64.
36. Boström SL, Hansson GF, Kiaer M, et al. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul Fibrinolysis 2003;14:457-62.
37. Green L, Lawrie AS, Patel S, et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol 2010;15:469-76.
38. Perzbon R, Harwardt M, Heitmeier S, et al. The effect of the oral direct factor Xa inhibitor rivaroxaban on tissue factor mediated in vitro platelet aggregation is enhanced by a P2Y receptor block (abstract). J Thromb Haemost 2011;9:74.
39. Furugohri T, Sugiyama N, Morishima Y, et al. Antithrombin-independent thrombin inhibitors, but not direct Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost 2011;106:1076-83.
40. Christersson C, Oldgren J, Wallentin L, et al. Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med 2011;270:215-23.
41. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with and without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26.
42. Eikelboom J, Oldgren J, Reilly P, et al. No evidence of platelet activation in patients with atrial fibrillation who are treated with dabigatran: a substudy of the RELY Trial (abstract). J Thromb Haemost 2011;9:346.
43. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the Randomized Evaulation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2011;123:2363-72.
44. van Es RF, Jonker JJC, Verheugt FWA, et al., for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.